AML

Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail
Fierce Biotech
Fri, 12/20/24 - 11:08 am
Apollomics
China
AML
uproleselan
Foghorn gives up on sole wholly owned clinical asset after phase 1 leukemia failure
Fierce Biotech
Mon, 12/16/24 - 11:27 am
Foghorn Therapeutics
AML
FHD-286
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action
Medpage Today
Wed, 11/27/24 - 09:59 pm
Bluebird Bio
Skysona
FDA
myelodysplastic syndrome
AML
cALD
Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug ahead of push to FDA
Fierce Biotech
Thu, 11/21/24 - 11:14 am
Kyowa Kirin
Kura Oncology
ziftomenib
AML
Cellectis drops one of its 3 clinical-stage CAR-Ts
Fierce Biotech
Tue, 11/5/24 - 06:19 pm
Cellectis
CAR-T
UCART123
AML
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Fierce Biotech
Tue, 10/29/24 - 11:44 am
Novartis
MorphoSys
M&A
AML
pelabresib
Notable Labs hopes for success with Boehringer’s failed AML drug
Clinical Trials Arena
Fri, 02/23/24 - 10:35 am
Notable Labs
Boehringer Ingelheim
AML
volasertib
artificial intelligence
Faron’s Clever-1 drug shows promise in blood cancers
Pharmaphorum
Wed, 10/11/23 - 10:01 am
Faron Pharmaceuticals
bexmarilimab
AML
MDS
clinical trials
Syndax stops pivotal cancer trial early for efficacy but details disappoint, sending stock down
Fierce Biotech
Mon, 10/2/23 - 10:26 am
Syndax Pharmaceuticals
clinical trials
revumenib
AML
Mendus shows early comparability data for its universal cancer vaccine
Clinical Trials Arena
Thu, 09/21/23 - 10:39 am
Mendus
vididencel
AML
ovarian cancer
vaccines
Foghorn Therapeutics doses first patient in AML therapy trial
Clinical Trials Arena
Fri, 09/1/23 - 11:57 am
Foghorn Therapeutics
FHD-286
AML
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Fierce Biotech
Mon, 08/21/23 - 10:06 am
Gilead Sciences
MDS
magrolimab
clinical trials
AML
FDA puts 2seventy CAR-T trial on hold in wake of patient death
Fierce Biotech
Mon, 08/14/23 - 10:06 am
2seventy bio
clinical trials
FDA
patient deaths
AML
CAR-T
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
Pharmaphorum
Fri, 07/21/23 - 10:08 am
Daiichi Sankyo
Vanflyta
FDA
AML
Foghorn Abandons Uveal Melanoma Program after Subpar Phase I Results
BioSpace
Thu, 06/29/23 - 11:48 am
Foghorn Therapeutics
uveal melanoma
AML
FHD-286
Kura files $100m offer after menin inhibitor results in AML
Pharmaphorum
Wed, 06/14/23 - 10:25 am
Kura Oncology
ziftomenib
AML
stock offering
EHA
Death triggers pause of 2seventy CAR-T cell therapy leukemia trial
Fierce Biotech
Wed, 06/14/23 - 10:18 am
2seventy bio
Bluebird Bio
CAR-T
patient death
clinical trials
AML
Mendus cancer vaccine succeeds in Phase II AML trial
Clinical Trials Arena
Mon, 06/12/23 - 10:19 am
Mendus
vididencel
AML
clinical trials
Affimed begins subject dosing in acute myeloid leukaemia therapy trial
Clinical Trials Arena
Thu, 03/30/23 - 10:12 am
Affimed
clinical trials
AFM283
AML
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
Tue, 03/28/23 - 10:41 pm
OncoVerity
Argenx
AML
cusatuzumab

Pages